Esphera SynBio, an Ottawa, Ontario, Canada-based synthetic biology company, raised USD2M in Seed funding.
Backers included GKCC and FACIT.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Dr. Brian Lichty, Esphera is a seed stage biotechnology company combining technologies developed at McMaster University and the Ottawa Hospital Research Institute, using synthetic biology approaches to modify cells through the expression of proprietary transgenes causing the production of engineered exosomes that serve as nanomedicines for the treatment and prevention of human disease. It is developing cancer immunotherapies, vaccines and immunomodulatory therapies for a range of human diseases.
FinSMEs
08/01/2024